Kailera Therapeutics reports company developments tied to its transition into the public markets and its clinical-stage obesity therapeutics business. News items cover the pricing and closing of its initial public offering, the listing of KLRA common stock on the Nasdaq Global Select Market, and equity financing associated with its development-stage operations.
Company updates also frame Kailera as an advanced clinical-stage biotechnology issuer focused on obesity care, with public communications centered on capital formation, listing status, and product-candidate development in GLP-1 based obesity therapeutics.
Kailera Therapeutics (Nasdaq: KLRA) presented Phase 1 ribupatide injection data at EASD 2026 showing similar drug exposure across three injection sites. In 51 adults with obesity or overweight, upper-arm and thigh injections produced exposure similar to abdominal injections. Most treatment-emergent adverse events were mild and gastrointestinal; no new safety signals were identified.
Partner Hengrui Pharma also presented Phase 1 data for HRS-4729 (KAI-4729). At Week 12, the multiple-dose 12 mg group (N=10) achieved mean weight loss of up to 16.0% from baseline and a 67.3% mean reduction in liver fat content. Most adverse events were mild to moderate and gastrointestinal-related. Kailera plans a KAI-4729 Phase 1 trial outside China in 2026, with data expected in 2027. Ribupatide injection is in global Phase 3 trials; Kailera plans global Phase 3 trials of oral ribupatide in the first half of 2027.
Kailera Therapeutics (KLRA) completed enrollment across three global Phase 3 trials evaluating ribupatide injection for people with obesity or overweight. Kailera now expects topline data in mid-2028. Ribupatide is an investigational once-weekly injection that activates GLP-1 and GIP receptors.
KaiNETIC-1 enrolled approximately 2,500 adults without type 2 diabetes; KaiNETIC-2 enrolled approximately 1,200 adults with type 2 diabetes. KaiNETIC-3 enrolled approximately 1,200 adults with a body mass index (BMI) of 35 kg/m² or greater and without type 2 diabetes. The trials assess weight change at Week 76; KaiNETIC-2 also assesses blood sugar through hemoglobin A1c, while KaiNETIC-3 compares weight change against placebo and semaglutide 2.4 mg. Treatment runs for 76 weeks, with ribupatide doses up to 10 mg. Kailera also plans to initiate global Phase 3 trials of oral ribupatide in obesity in the first half of 2027.
Kailera Therapeutics (Nasdaq: KLRA) will participate in two investor conferences in September 2026 focused on healthcare and cardiometabolic disease.
The company will join a fireside chat at the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Wednesday, September 23, 2026, at 9:40 a.m. ET. Kailera will also host a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 11:30 a.m. ET. Live webcasts of both events will be available on the Events page of Kailera’s investor website.
Kailera Therapeutics (Nasdaq: KLRA) reported second quarter 2026 results and detailed progress across its GLP‑1–based obesity pipeline. The global Phase 3 KaiNETIC program of ribupatide injection in obesity remains on track with three trials enrolling over 4,700 participants and data anticipated in 2028, while a U.S. Phase 2b high‑dose obesity trial is fully enrolled with data expected in mid‑2027. An IND for ribupatide oral is active with the U.S. FDA, supporting planned global Phase 3 obesity trials in the first half of 2027. Kailera is also running a global Phase 2 obesity trial of oral GLP‑1 agonist KAI‑7535 and preparing a Phase 1 trial for tri‑agonist KAI‑4729 in 2026. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $1,171.8 million, which Kailera expects will fund operations into mid‑2028, alongside higher R&D spending of $101.1 million and a quarterly net loss of $111.3 million.
Kailera Therapeutics (Nasdaq: KLRA) appointed veteran technical operations leader Nur Nicholson as Chief Technology Officer, effective August 31, 2026. Nicholson will oversee manufacturing and supply chain strategy as Kailera advances its late-stage obesity pipeline, including global Phase 3 trials of once-weekly injectable ribupatide and preparations for a Phase 3 oral program.
Kailera highlights four clinical-stage GLP-1–based candidates: ribupatide injection (KAI-9531), a once-daily oral ribupatide formulation in development, KAI-7535 (once-daily oral GLP-1 agonist), and KAI-4729 (once-weekly injectable GLP-1/GIP/glucagon tri-agonist).
Kailera Therapeutics (KLRA) reported positive topline data from two Hengrui Pharma Phase 3 trials of oral GLP-1 agonist HRS-7535/KAI-7535 in China.
In obesity/overweight, mean weight loss reached up to 10.9% at Week 44 and 11.1% at Week 50. In type 2 diabetes, HbA1c fell by 1.50%–1.68% across doses, with liver safety findings consistent with prior data and no observed liver safety signals. Kailera is running a global Phase 2 obesity trial, started April 2026, with data expected in 2027.
Kailera Therapeutics (KLRA), a clinical-stage obesity-focused biotech, appointed Kathleen Tregoning as Chief Corporate Affairs Officer. The hire supports advancement of its late-stage obesity trials and engagement with stakeholders in a rapidly evolving treatment landscape.
Tregoning brings 20+ years in global corporate affairs, with senior roles at Cerevel Therapeutics, Sanofi, and Biogen, and board positions at Compass Pathways (CMPS) and Spero Therapeutics (SPRO).
Hengrui Pharma and Kailera Therapeutics (NASDAQ:KLRA) presented new clinical data for ribupatide, a GLP-1/GIP dual agonist for obesity, at ADA 2026.
Phase 2 oral data in China showed up to 12.1% mean weight loss at 26 weeks and up to 38.6% achieving ≥15% weight loss, with mainly mild gastrointestinal events and no discontinuations for GI issues. A Phase 1 single-dose injection study outside China reported similar exposure and tolerability in Asian and non-Asian participants and mean weight loss of 1.4–5.5% vs 0.4% with placebo at Day 29.
Kailera Therapeutics (Nasdaq: KLRA), a clinical-stage biotech focused on obesity care, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 a.m. EDT. A live webcast and 90-day replay will be available on the company’s investor website.
Kailera (Nasdaq: KLRA) reported Q1 2026 results and obesity pipeline updates. As of March 31, 2026, cash, equivalents and marketable securities were $581.9M, and, with $718.8M IPO gross proceeds, are expected to fund operations into mid‑2028. Q1 net loss was $78.9M.
The company initiated five late-stage global obesity trials, including the Phase 3 KaiNETIC program for ribupatide injection, and reported topline data: ribupatide oral showed up to 12.1% mean weight loss, KAI‑4729 up to 16.0% weight loss, and KAI‑7535 achieved HbA1c reductions up to 1.68%.